Evaluation of the effect of acetyl L-carnitine on experimental cisplatin nephrotoxicity

Chemotherapy

Volumn 55, Issue 6, 2009, Pages 451-459

  Tufekci, Ozlem ^a   Gunes, Dilek ^e   Özoǧul, Candan ^b   Kolatan, Efsun ^c   Altun, Zekiye ^e   Yilmaz, Osman ^c   Aktaş, Safiye ^e   Erbayraktar, Zübeyde ^e   Kirkim, Günay ^d   Mutafoǧlu, Kamer ^a   Soylu, Alper ^e   Şerbetçioǧlu, Bülent ^d   Güneri, Enis Alpin ^d   Olgun, Nur ^e  

^a Departments of Pediatric Dentistry   (Turkey)

^b Departments of Histology   (Turkey)

^c Laboratory Animal Science   (Turkey)

^d Departments of Otorhinolaryngology   (Turkey)

^e DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Acetyl L carnitine; Apoptosis; Cisplatin; Nephrotoxicity; Ultrastructure

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CISPLATIN; CISPLATIN EBEWE; CREATININE; LEVACECARNINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; ELECTRON MICROSCOPY; FEMALE; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY DYSFUNCTION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; REHYDRATION; RENAL PROTECTION;

ACETYLCARNITINE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 8; CASPASE 9; CISPLATIN; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MICROSCOPY, ELECTRON; RATS; RATS, WISTAR; VITAMIN B COMPLEX;

EID: 71249140647     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000240020     Document Type: Article

References (51)

1. Kelland L: The resurgence of platinum based cancer chemotherapy. Nat Rev Cancer 2007; 7: 573-584.
2. Wang D, Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4: 307-320.
3. Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9-23.
4. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-7279.
5. Sastry J, Kellie SJ: Severe neurotoxicity, ototoxicity and nephrotoxicity following highdose cisplatin and amifostine. Pediatr Hematol Oncol 2005; 22: 441-445.
6. Arany I, Safirstein RL: Cisplatin nephrotoxicity. Semin Nephrol 2003; 23: 460-464.
7. Boulikas T, Vougiouka M: Cisplatin and platinum drugs at the molecular level. Oncol Rep 2003; 10: 1663-1682.
8. Hofmann MA, Gabriel V, Milling A, Kiecker F, Sterry W, Trefzer U: High-dose platinum combination therapy in pretreated patients with disseminated melanoma. Chemotherapy 2007; 53: 422-428.
9. Yao X, Panichpisal K, Kurtzman N, Nugent K: Cisplatin nephrotoxicity: a review. Am J Med Sci 2007; 334: 115-124.
10. Pabla N, Dong Z: Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008; 73: 994-1007.
11. Monograph. L-carnitine. Altern Med Rev 2005; 10: 42-50.
12. Calabrese V, Giuffrida Stella AM, Calvani M, Butterfield DA: Acetylcarnitine and cellular stress response: roles in nutritional redox homeostasis and regulation of longevity genes. J Nutr Biochem 2006; 17: 73-88.
13. Bremer J: Carnitine-metabolism and functions. Physiol Rev 1983; 63: 1420-1480.
14. Arockia Rani PJ, Panneerselvam C: Carnitine as a free radical scavenger in aging. Exp Gerontol 2001; 36: 1713-1726.
15. Arrigoni-Martelli E, Caso V: Carnitine protects mitochondria and removes toxic acyls from xenobiotics. Drugs Exp Clin Res 2001; 27: 27-49.
16. Binienda ZK, Ali SF: Neuroprotective role of L -carnitine in the 3-nitropropionic acid induced neurotoxicity. Toxicol Lett 2001; 125: 67-73.
17. Gülçin I: Antioxidant and antiradical activities of L -carnitine. Life Sci 2006; 78: 803-811.
18. Calò LA, Pagnin E, Davis PA, et al: Antioxidant effect of L -carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int J Cardiol 2006; 107: 54-60.
19. Ferraresi R, Troiano L, Roat E, et al: Protective effect of acetyl- L -carnitine against oxidative stress induced by antiretroviral drugs. FEBS Lett 2006; 580: 6612-6616.
20. Barhwal K, Singh SB, Hota SK, Jayalakshmi K, Ilavazhagan G: Acetyl- L -carnitine ameliorates hypobaric hypoxic impairment and spatial memory deficits in rats. Eur J Pharmacol 2007; 570: 97-107.
21. Di Cesare Mannelli L, Ghelardini C, Calvani M, et al: Protective effect of acetyl- L -carnitine on the apoptotic pathway of peripheral neuropathy. Eur J Neurosci 2007; 26: 820-827.
22. Di Cesare Mannelli L, Ghelardini C, Calvani M, et al: Neuroprotective effects of acetyl- L - carnitine on neuropathic pain and apoptosis: a role for the nicotinic receptor. J Neurosci Res 2009; 87: 200-207.
23. Zhu X, Sato EF, Wang Y, Nakamura H, Yodoi J, Inoue M: Acetyl- L -carnitine suppresses apoptosis of thioredoxin 2-deficient DT40 cells. Arch Biochem Biophys 2008; 478: 154-160.
24. Yano T, Itoh Y, Yamada M, Eqashira N, Oishi R: Combined treatment with L -carnitine and a pan-caspase inhibitor effectively reverses amiodarone-induced injury in cultured human lung epithelial cells. Apoptosis 2008; 13: 543-552.
25. Ishii T, Shimpo Y, Matsuoka Y, Kinoshita K: Anti-apoptotic effect of acetyl- L -carnitine and L -carnitine in primary cultured neurons. Jpn J Pharmacol 2000; 83: 119-124.
26. Sayed-Ahmed MM, Eissa MA, Kenawy SA, Mostafa N, Calvani M, Osman AM: Progression of cisplatin-induced nephrotoxicity in a carnitine-depleted rat model. Chemotherapy 2004; 50: 162-170.
27. Chang B, Nishikawa M, Sato E, Utsumi K, Inoue M, et al: L -Carnitine inhibits cisplatininduced injury of the kidney and small intestine. Arch Biochem Biophys 2002; 405: 55-64.
28. Aleisa AM, Al-Majed AA, Al-Yahya AA, et al: Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl- L -carnitine in rat kidney tissues. Clin Exp Pharmacol Physiol 2007; 34: 1252-1259.
29. Kukner A, Colakoglu N, Kara H, Oner H, Ozogul C, Ozan E: Ultrastructural changes in the kidney of rats with acute exposure to cadmium and effects of exogenous metallothionein. Biol Trace Elem Res 2007; 119: 137-146.
30. Pekcetin C, Ergur BU, Kiray M, et al: The protective effects of trimetazidine on testicular ischemia and reperfusion injury in rats. Pediatr Surg Int 2007; 23: 1113-1118.
31. Ramesh G, Reeves WB: TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 2003; 285:F610-F618.
32. Ramesh G, Reeves WB: TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002; 110: 835-842.
33. Ramesh G, Reeves WB: Inflammatory cytokines in acute renal failure. Kidney Int Suppl 2004; 91:S56-S61.
34. Miguel-Carrasco JL, Mate A, Monserrat MT, Arias JL, Aramburu O, Vazquez CM: The role of inflammatory markers in the cardioprotective effect of L -carnitine in L -NAMEinduced hypertension. Am J Hypertens 2008; 21: 1231-1237.
35. Tastekin N, Aydogdu N, Dokmeci D, et al: Protective effects of L -carnitine and alphalipoic acid in rats with adjuvant arthritis. Pharmacol Res 2007; 5: 303-310.
36. Savica V, Santoro D, Mazzaglia G, et al: L - carnitine infusions may suppress serum Creactive protein and improve nutritional status in maintenance hemodialysis patients. J Ren Nutr 2005; 15: 225-230.
37. Arafa HM: Carnitine deficiency aggravates carboplatin nephropathy through deterioration of energy status, oxidant/anti-oxidant balance, and inflammatory endocoids. Toxicology 2008; 254: 51-60.
38. Fenoglio C, Boicelli CA, Ottone M, Addario C, Chiari P, Viale M: Protective effect of procaine hydrochloride on cisplatin-induced alterations in rat kidney. Anticancer Drugs 2002; 13: 1043-1054.
39. Kohn S, Fradis M, Ben-David J, Zidan J, Robinson E: Nephrotoxicity of combined treatment with cisplatin and gentamicin in the guinea pig: glomerular injury findings. Ultrastruct Pathol 2002; 26: 371-382.
40. Kitada N, Takara K, Itoh C, Minegaki T, Tsujimoto M, Sakaeda T, Yokoyama T: Comparative analysis of cell injury after exposure to antitumor platinum derivatives in kidney tubular epithelial cells. Chemotherapy 2008; 54: 217-223.
41. Yilmaz HR, Iraz M, Sogut S, et al: The effects of erdosteine on the activities of some metabolic enzymes during cisplatin-induced nephrotoxicity in rats. Pharmacol Res 2004; 50: 287-290.
42. Pacifici EH, McLeod LL, Sevanian A: Lipid hydroperoxide-induced peroxidation and turnover of endothelial cell phospholipids. Free Radic Biol Med 1994; 17: 297-309. (Pubitemid 24296150)
43. Madesh M, Balasubramanian KA: Activation of liver mitochondrial phospholipase A2 by superoxide. Arch Biochem Biophys 1997; 15: 187-192.
44. Sultan A, Sokolove PM: Free fatty acid effects on mitochondrial permeability: an overview. Arch Biochem Biophys 2001; 386: 52-61.
45. Furuno T, Kanno T, Arita K, et al: Roles of long chain fatty acids and carnitine in mitochondrial membrane permeability transition. Biochem Pharmacol 2001; 62: 1037-1046.
46. Green DR, Reed JC: Mitochondria and apoptosis. Science 1998; 281: 1309-1312.
47. Sparagna GC, Hickson-Bick DL, Buja LM, McMillin JB: A metabolic role for mitochondria in palmitate-induced cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol 2000; 279:H2124-H2132.
48. Schönfeld P, Bohnensack R: Fatty acid-promoted mitochondrial permeability transition by membrane depolarization and binding to the ADP/ATP carrier. FEBS Lett 1997; 420: 167-170.
49. Pastorino JG, Snyder JW, Serroni A, Hoek JB, Farber JL: Cyclosporin and carnitine prevent the anoxic death of cultured hepatocytes by inhibiting the mitochondrial permeability transition. J Biol Chem 1993; 268: 13791-13798.
50. Kawai Y, Nakao T, Kunimura N, Kohda Y, Gemba M: Relationship of intracellular calcium and oxygen radicals to cisplatin-related renal cell injury. J Pharmacol Sci 2006; 100: 65-72.
51. Traina G, Bernardi R, Rizzo M, Calvani M, Durante M, Brunelli M: Acetyl- L -carnitine up-regulates expression of voltage-dependent anion channel in the rat brain. Neurochem Int 2006; 48: 67367-67368.